Search

Your search keyword '"Merola E"' showing total 133 results
Start Over Author "Merola E"
133 results on '"Merola E"'

1. Clinical impact of nasal budesonide treatment on COPD patients with coexistent rhinitis

Author

Calabrese C, Costigliola A, Maffei M, Simeon V, Perna F, Tremante E, Merola E, Leone CA, and Bianco A

Subjects
COPD, Rhinitis, CAT, SNOT22, mMRC, Budesonide, Diseases of the respiratory system, RC705-779
Abstract

Cecilia Calabrese,1 Adriano Costigliola,1 Marianna Maffei,2 Vittorio Simeon,3 Francesco Perna,4 Eugenio Tremante,2 Elena Merola,5 Carlo Antonio Leone,2 Andrea Bianco1 1Department of Cardio-Thoracic and Respiratory Sciences, Monaldi Hospital, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Ear Nose and Throat Unit and Neck Surgery, Monaldi Hospital, Naples, Italy; 3Medical Statistics Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy; 4Department of Clinical Medicine and Surgery, Monaldi Hospital, University “Federico II”, Naples, Italy; 5Bronchoscopic Unit, Public Hospital, Eboli, Italy Background: A high percentage of patients with COPD report chronic nasal symptoms. The study aims to evaluate the clinical impact of a 2-month treatment with inhaled nasal budesonide (100 µg per nostril twice daily) in patients affected by COPD with chronic rhinitis comorbidity.Patients and methods: Fifty-three stable COPD patients in therapy according to the Global initiative for chronic Obstructive Lung Disease recommendations were enrolled; 49 completed the study. At enrollment (visit 0), patients underwent skin prick test and rhinoscopy. At visit 0 and after 1 month (visit 1) and 2 months (visit 2) of therapy with nasal budesonide, patients underwent spirometry, and COPD assessment test (CAT), Sinonasal Outcome Test (SNOT 22), and modified Medical Research Council dyspnea scale were administered. Differences in continuous variables, after 2 months of treatment with nasal budesonide, were evaluated using a paired t-test or Wilcoxon matched-pairs signed-ranks test.Results: Two months of treatment with nasal budesonide showed a significant statistical improvement in the total scores of CAT, SNOT 22, and modified Medical Research Council (p

Published
2018

2. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence

Author

Merola, E., Pascher, A., Rinke, A., Bartsch, D. K., Zerbi, A., Nappo, G., Carnaghi, C., Ciola, M., McNamara, M. G., Zandee, W., Bertani, E., Marcucci, S., Modica, R., Grützmann, R., Fazio, N., de Herder, W., Valle, J. W., Gress, T. M., Fave, G. Delle, de Pretis, G., Perren, A., Wiedenmann, B., and Pavel, M. E.

Published
2022
Full Text
View/download PDF

3. ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors—Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence

Author

Merola, E., Pascher, A., Rinke, A., Bartsch, D. K., Zerbi, A., Nappo, G., Carnaghi, C., Ciola, M., McNamara, M. G., Zandee, W., Bertani, E., Marcucci, S., Modica, R., Grützmann, R., Fazio, N., de Herder, W., Valle, J. W., Gress, T. M., Delle Fave, G., de Pretis, G., Perren, A., Wiedenmann, B., and Pavel, M. E.

Published
2022
Full Text
View/download PDF

4. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

Author

Panzuto, F., Maccauro, M., Campana, D., Faggiano, A., Massironi, S., Pusceddu, S., Spada, F., Ferone, D., Modica, R., Grana, C. M., Ferolla, P., Rinzivillo, M., Badalamenti, G., Zatelli, M. C., Gelsomino, F., De Carlo, E., Bartolomei, M., Brizzi, M. P., Cingarlini, S., Versari, A., Fanciulli, G., Arvat, E., Merola, E., Cives, M., Tafuto, S., Baldari, S., and Falconi, M.

Published
2021
Full Text
View/download PDF

6. ASO Visual Abstract

Author

Merola, E, Pascher, A, Rinke, A, Bartsch, D K, Zerbi, A, Nappo, G, Carnaghi, C, Ciola, M, McNamara, M G, Zandee, W, Bertani, E, Marcucci, S, Modica, R, Grützmann, R, Fazio, N, de Herder, W, Valle, J W, Gress, T M, Delle Fave, G, de Pretis, G, Perren, A, Wiedenmann, B, Pavel, M E, Internal Medicine, Merola, E., Pascher, A., Rinke, A., Bartsch, D. K., Zerbi, A., Nappo, G., Carnaghi, C., Ciola, M., Mcnamara, M. G., Zandee, W., Bertani, E., Marcucci, S., Modica, R., Gruetzmann, R., Fazio, N., de Herder, W., Valle, J. W., Gress, T. M., Delle Fave, G., de Pretis, G., Perren, A., Wiedenmann, B., and Pavel, M. E.

Subjects
Pancreatic Neoplasms, Survival Rate, Neuroendocrine Tumors, Oncology, Risk Factors, 570 Life sciences, biology, Humans, Surgery, Neoplasm Recurrence, Local, 610 Medicine & health, Prognosis, Disease-Free Survival, Retrospective Studies
Published
2022

7. The role of rewilding in combating biodiversity loss.

Author

Merola, E.

Subjects
*ENVIRONMENTAL degradation, *WILDLIFE reintroduction, *HABITAT destruction, *BIOLOGICAL extinction, *CLIMATE change, *PLANT extracts
Abstract

Biodiversity loss is one of the most pressing environmental challenges of our time, with species extinction rates accelerating due to habitat destruction, climate change, and other human activities. To combat this crisis, a concept known as "rewilding" has gained momentum. Rewilding involves restoring and conserving ecosystems by allowing natural processes to unfold with minimal human interference. In this article, we will explore the concept of rewilding, its principles, and its critical role in stemming biodiversity loss. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%?

Author

MS Endocriene Oncologie, Cancer, Merola, E, Alonso Gordoa, T, Zhang, P, Al-Toubah, T, Pelle, E, Kolasińska-Ćwikła, A, Zandee, W T, Laskaratos, F M, de Mestier, L, Lamarca, A, Hernando, J, Cwikla, J B, Strosberg, J, de Herder, W W, Caplin, M, Cives, M, van Leeuwaarde, R S, MS Endocriene Oncologie, Cancer, Merola, E, Alonso Gordoa, T, Zhang, P, Al-Toubah, T, Pelle, E, Kolasińska-Ćwikła, A, Zandee, W T, Laskaratos, F M, de Mestier, L, Lamarca, A, Hernando, J, Cwikla, J B, Strosberg, J, de Herder, W W, Caplin, M, Cives, M, and van Leeuwaarde, R S

Published
2021

9. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

Author

Panzuto, F., primary, Maccauro, M., additional, Campana, D., additional, Faggiano, A., additional, Massironi, S., additional, Pusceddu, S., additional, Spada, F., additional, Ferone, D., additional, Modica, R., additional, Grana, C. M., additional, Ferolla, P., additional, Rinzivillo, M., additional, Badalamenti, G., additional, Zatelli, M. C., additional, Gelsomino, F., additional, De Carlo, E., additional, Bartolomei, M., additional, Brizzi, M. P., additional, Cingarlini, S., additional, Versari, A., additional, Fanciulli, G., additional, Arvat, E., additional, Merola, E., additional, Cives, M., additional, Tafuto, S., additional, Baldari, S., additional, and Falconi, M., additional

Published
2020
Full Text
View/download PDF

12. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications

Author

Merola E, Pavel ME, Panzuto F, Capurso G, Cicchese N, Rinke A, Gress TM, Iannicelli E, Prosperi D, Pizzichini P, Prasad V, Kump P, Lipp R, Partelli S, Falconi M, Wiedenmann B, Delle Fave G, Merola, E, Pavel, Me, Panzuto, F, Capurso, G, Cicchese, N, Rinke, A, Gress, Tm, Iannicelli, E, Prosperi, D, Pizzichini, P, Prasad, V, Kump, P, Lipp, R, Partelli, S, Falconi, M, Wiedenmann, B, and Delle Fave, G

Published
2017

17. Bone metastases in patients with neuroendocrine neoplasms: A survey of natural history and clinical management

Author

Fazio, N., primary, Maisonneuve, P., additional, Frezza, A.M., additional, Ibrahim, T., additional, La Salvia, A., additional, Tafuto, S., additional, Pusceddu, S., additional, Marconcini, R., additional, Silvestris, F., additional, Campana, D., additional, Santini, D., additional, Faggiano, A., additional, Massironi, S., additional, De Marinis, L., additional, Rubini, G., additional, Merola, E., additional, Antonuzzo, L., additional, Amoroso, V., additional, Puliafito, I., additional, and Spada, F., additional

Published
2017
Full Text
View/download PDF

18. P312"Real zero" fluoroscopy AVNRT ablation

Author

Zoppo, F., primary, Indiani, S., additional, Merola, E., additional, Favaro, G., additional, Lupo, A., additional, Zerbo, F., additional, Bacchiega, E., additional, Brazzolotto, A., additional, Bottazzo, V., additional, and Lago, L., additional

Published
2017
Full Text
View/download PDF

46. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

Author

Maria Chiara Zatelli, Fabio Gelsomino, Emanuela Arvat, Giuseppe Badalamenti, Annibale Versari, Sergio Baldari, Sara Pusceddu, Roberta Modica, Salvatore Tafuto, Elettra Merola, Mirco Bartolomei, Antongiulio Faggiano, Mauro Cives, E. De Carlo, Massimo Falconi, Maria Pia Brizzi, Francesco Panzuto, Chiara Maria Grana, Giuseppe Fanciulli, Francesca Spada, Diego Ferone, M Maccauro, Davide Campana, S Cingarlini, Sara Massironi, Piero Ferolla, Maria Rinzivillo, Panzuto F., Maccauro M., Campana D., Faggiano A., Massironi S., Pusceddu S., Spada F., Ferone D., Modica R., Grana C.M., Ferolla P., Rinzivillo M., Badalamenti G., Zatelli M.C., Gelsomino F., De Carlo E., Bartolomei M., Brizzi M.P., Cingarlini S., Versari A., Fanciulli G., Arvat E., Merola E., Cives M., Tafuto S., Baldari S., Falconi M., Panzuto, F., Maccauro, M., Campana, D., Faggiano, A., Massironi, S., Pusceddu, S., Spada, F., Ferone, D., Modica, R., Grana, C. M., Ferolla, P., Rinzivillo, M., Badalamenti, G., Zatelli, M. C., Gelsomino, F., De Carlo, E., Bartolomei, M., Brizzi, M. P., Cingarlini, S., Versari, A., Fanciulli, G., Arvat, E., Merola, E., Cives, M., Tafuto, S., Baldari, S., and Falconi, M.

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Antineoplastic Agents, 030209 endocrinology & metabolism, Neuroendocrine tumors, Medical Oncology, NO, 03 medical and health sciences, Patient safety, 0302 clinical medicine, Endocrinology, Ambulatory care, Neuroendocrine tumor, Surveys and Questionnaires, Epidemiology, Pandemic, Humans, Medicine, LS4_3, Pandemics, Patient Care Team, business.industry, COVID-19, Multidisciplinary team, Continuity of Patient Care, medicine.disease, Management, Clinical trial, Italy, management, multidisciplinary team, neuroendocrine tumors, pandemic, peptide receptors radionuclide therapy, SARS-CoV2, 030220 oncology & carcinogenesis, Radionuclide therapy, s COVID-19, SARS-CoV2, Pandemic, Neuroendocrine tumors, Multidisciplinary team, Management ,Peptide receptors, radionuclide therapy, Peptide receptors radionuclide therapy, Original Article, Female, business, Health care quality
Abstract

Introduction The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination. Methods A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020 Results The main modification in the centers’ activity consisted of decreases in newly diagnosed NEN patients (− 76.8%), decreases in performed surgical procedures (− 58%), delays to starting peptide receptor radionuclide therapy (45.5%), postponed/canceled follow-up examinations (26%), and canceled multidisciplinary teams’ activity (20.8%). A low proportion of centers (

Published
2021

47. Clinical impact of nasal budesonide treatment on COPD patients with coexistent rhinitis

Author

Cecilia Calabrese, Andrea Bianco, Adriano Costigliola, Carlo Antonio Leone, Elena Merola, Marianna Maffei, Francesco Perna, Vittorio Simeon, Eugenio Tremante, Calabrese, C, Costigliola, A, Maffei, M, Simeon, V, Perna, F, Tremante, E, Merola, E, Leone, Ca, Bianco, A., Calabrese, C., Costigliola, A., Maffei, M., Simeon, V., Perna, F., Tremante, E., Merola, E., and Leone, C. A.

Subjects
Budesonide, Spirometry, Male, medicine.medical_specialty, budesonide, Copd patients, Nostril, Anti-Inflammatory Agents, International Journal of Chronic Obstructive Pulmonary Disease, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, rhinitis, Quality of life, Internal medicine, medicine, COPD, Humans, 030223 otorhinolaryngology, Rhiniti, Administration, Intranasal, Original Research, Aged, SNOT22, lcsh:RC705-779, medicine.diagnostic_test, business.industry, SNOT 22, CAT, General Medicine, lcsh:Diseases of the respiratory system, Middle Aged, medicine.disease, Comorbidity, Obstructive lung disease, Anti-Inflammatory Agent, medicine.anatomical_structure, 030228 respiratory system, Italy, Quality of Life, Female, business, mMRC, medicine.drug, Human
Abstract

Background: A high percentage of patients with COPD report chronic nasal symptoms. The study aims to evaluate the clinical impact of a 2-month treatment with inhaled nasal budesonide (100 µg per nostril twice daily) in patients affected by COPD with chronic rhinitis comorbidity. Patients and methods: Fifty-three stable COPD patients in therapy according to the Global initiative for chronic Obstructive Lung Disease recommendations were enrolled; 49 completed the study. At enrollment (visit 0), patients underwent skin prick test and rhinoscopy. At visit 0 and after 1 month (visit 1) and 2 months (visit 2) of therapy with nasal budesonide, patients underwent spirometry, and COPD assessment test (CAT), Sinonasal Outcome Test (SNOT 22), and modified Medical Research Council dyspnea scale were administered. Differences in continuous variables, after 2 months of treatment with nasal budesonide, were evaluated using a paired t-test or Wilcoxon matched-pairs signed-ranks test. Results: Two months of treatment with nasal budesonide showed a significant statistical improvement in the total scores of CAT, SNOT 22, and modified Medical Research Council (p

Published
2018

48. Futilità e assenza: la cecità nell'ultimo Carlo Levi

Author

Gasperina Geroni, Riccardo, D. De Liso, V. Merola e S. Valerio, Di Maro, Maria, Petriccione, Matteo, and Gasperina Geroni, Riccardo

Subjects
Carlo Levi, cecità, Malattia, Quaderno a cancelli
Abstract

L'autore affronta il problema della cecità nel postumo Quaderno a cancelli di Carlo Levi, dimostrando in particolare quanto la malattia abbia permeato e plasmato l'opera.

Published
2021

49. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3

Author

Valentina Andreasi, Andreas Pascher, Felix J. Krendl, Claudio Doglioni, Stefano Partelli, Bertram Wiedenmann, Ruza Arsenic, Marianne Pavel, Stefan Staettner, Thomas M. Gress, Daniel Kaemmerer, Anja Rinke, Massimo Falconi, Elettra Merola, Merola, E., Falconi, M., Rinke, A., Staettner, S., Krendl, F., Partelli, S., Andreasi, V., Gress, T. M., Pascher, A., Arsenic, R., Doglioni, C., Kaemmerer, D., Wiedenmann, B., and Pavel, M. E.

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Population, Neuroendocrine neoplasms G3, 030209 endocrinology & metabolism, 03 medical and health sciences, 0302 clinical medicine, Recurrence, medicine, Overall survival, Humans, Radical surgery, education, Stage IV, Aged, Neoplasm Staging, Retrospective Studies, Curative intent, Chemotherapy, education.field_of_study, business.industry, Standard treatment, Patient Selection, General Medicine, Middle Aged, Surgery, Survival Rate, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, Female, Neoplasm Grading, Neoplasm Recurrence, Local, business, Radical resection, Stage iv
Abstract

Background Stage IV gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) G3 are the NENs with the worst prognosis. According to ENETS guidelines, platinum-based chemotherapy is the standard treatment for this population. Surgery is only considered in highly selected “resectable” NENs with usually lower Ki67. However, the role of surgery with curative intent has been poorly investigated. Objective To describe, in a retrospective series of stage IV GEP-NENs G3, overall survival (OS) and recurrence-free survival (RFS) rates after curatively intended surgery. Methods Multicenter analysis of stage IV GEP-NENs G3 receiving radical resection (R0/R1) from 2007 to 2017, with minimum post-surgical follow-up time of 3 months. Results Fifteen patients from 6 NEN referral centers, with median follow-up of 29 months (8-86), were included. Eight cases had a neuroendocrine carcinoma (NEC) and 7 a neuroendocrine tumor G3 (NET G3). Median OS after radical surgery was 59 months. All patients recurred, with a median RFS of 8 months. Conclusions Radical surgery might be considered for highly selected stage IV GEP-NENs G3. Larger series are needed to confirm these results.

Published
2020

50. De crimine vinario

Author

G. D. Merola, G.D. Merola e P. Santini, and Merola, G. D.

Subjects
portorium, Gallia, Fonteius
Abstract

Marco Fonteio, governatore della Gallia Narbonense tra il 76 e il 74 a.C., venne accusato dai provinciali di repetundae. La sua difesa fu assunta da Cicerone, che nel 70 (o forse nel 69 a.C.) pronunciò l’orazione Pro Fonteio, il cui testo ci è solo parzialmente giunto. L’accusa più odiosa che gli fu rivolta si riferisce al crimen vinarium: Fonteio istituì un portorium sul vino, con tariffe fisse e differenziate a seconda della località. Il contributo esamina la natura dell’illecito commesso da Fonteio e il significato economico dei dazi sul vino.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results